CEO Greetings
Organ Regeneration & Healthcare Innovation by Dr. INVIVO

ROKIT Healthcare is committed to bringing the best healthcare solutions from diverse talent and convergence of fields. No one is exempt from the problem of aging and age-related diseases, and the rhythm of regeneration and maximizing the potential of the human body is at the heart of what we do.

We want to provide safer and more effective organ regeneration platform services. I believe there is a paradigm shift in healthcare economics, and globally, there is a need for new therapeutic methods. Therefore, we would like to become a pioneer in this new paradigm of utilizing all advanced biotechnologies such as organ regeneration, single-cell RNA sequencing, tissue engineering, bio-inks, cell sheet, 3D bio fabrication, mRNA IPS technology, and bio platform technology.

Since 3D bio-fabrication technology is the best way to recapitulate the complex and functional human body, we have developed the therapeutic 3D bioprinter called Dr.INVIVO to use in tissue engineering and/or human organ regeneration. Dr.INVIVO is the world’s first sterile, all-in-one 3D organ regenerator. ROKIT’s autologous skin regeneration procedure using Dr.INVIVO has received regulatory approval for non-advanced therapy medicinal product (ATMP), meaning immediate access to the operating room (May 2019) by the European Medicines Agency (EMA) for the treatment of: 1) diabetic ulcer, 2) pressure ulcer, 3) scar revision, and 4) burn wound. During the clinical test, most of the patients with diabetic foot ulcer (DFU) showed a significant reduction in wound size with a distinct epithelization process for an average of 4 weeks after only one-time treatment of MA-ECM. In addition, the appropriate design of bio-inks, biomaterials, and artificial intelligence technology can promise an effective customized 3D bioprinting system to regenerate human tissue and organs.

I am excited to share our core organ platforms. We will provide organ regeneration platforms where the medical world can utilize our protocol, machine, material, and patient’s own cell. Please join us to open a new era of organ regeneration!

You, Seokhwan

Chairman/CEO